Company Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Verve Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.01 ^USD	-5.50%		-6.24%	-56.89%

May. 08	Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102	CI

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Companyâs lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Number of employees: 255

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	2	100.0 %	12	100.0 %	+505.77%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	2	100.0 %	12	100.0 %	+505.77%

Managers	Title	Age	Since
Sekar Kathiresan FOU	Founder	52	17-12-31
Allison Dorval DFI	Director of Finance/CFO	48	21-11-28
Andrew Ashe PSD	President	57	18-07-31
Jason Politi CTO	Chief Tech/Sci/R&D Officer	47	21-01-31
Richard Falzone CTO	Chief Tech/Sci/R&D Officer	50	21-03-31
Joan Nickerson ADM	Chief Administrative Officer	56	21-03-31
Troy Lister CTO	Chief Tech/Sci/R&D Officer	-	22-04-30
Andrew Bellinger CTO	Chief Tech/Sci/R&D Officer	-	19-09-30
Fred Fiedorek CTO	Chief Tech/Sci/R&D Officer	69	23-09-17
Andrew Sheely CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Burt Adelman FOU	Founder	71	17-12-31
Lonnel Coats BRD	Director/Board Member	58	22-08-07
Michael MacLean BRD	Director/Board Member	58	21-04-30
Sheila Mikhail BRD	Director/Board Member	57	21-03-31
Krishna Yeshwant BRD	Director/Board Member	46	18-07-31
Alexander Cumbo BRD	Director/Board Member	53	22-06-08
Sekar Kathiresan FOU	Founder	52	17-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	83,965,493	77,839,757 ( 92.70 %)	0	92.70 %

Name	Equities	%	Valuation
ALPHABET INC. 15.72 %	12,349,086	15.72 %	164 M $
Vanguard Fiduciary Trust Co. 8.060 %	6,331,312	8.060 %	84 M $
ARK Investment Management LLC 7.690 %	6,040,476	7.690 %	80 M $
BlackRock Advisors LLC 6.420 %	5,042,690	6.420 %	67 M $
James R Singer 6.365 %	5,000,000	6.365 %	66 M $
Federated Global Investment Management Corp. 5.067 %	3,980,372	5.067 %	53 M $
STATE STREET CORPORATION 4.923 %	3,866,764	4.923 %	51 M $
T. Rowe Price Investment Management, Inc. 4.041 %	3,174,352	4.041 %	42 M $
Fidelity Management & Research Co. LLC 3.913 %	3,073,841	3.913 %	41 M $
Casdin Capital LLC 3.831 %	3,009,094	3.831 %	40 M $

Verve Therapeutics, Inc.

201 Brookline Avenue Suite 601

02215, Boston

http://www.vervetx.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.01 USD

Average target price

26.89 USD

Spread / Average Target

+347.40%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
VERVE THERAPEUTICS, INC.	-56.89%	505M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research